Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015. ,
The changing pattern of kidney cancer incidence and mortality in Europe, BJU Int, vol.101, pp.949-958, 2008. ,
Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States, J. Urol, vol.191, pp.1665-1670, 2001. ,
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur. Urol, vol.70, pp.93-105, 2016. ,
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas, Sci. Rep, vol.6, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01357776
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin. Cancer Res, vol.13, issue.2, pp.680-684, 2007. ,
Signaling pathways in renal cell carcinoma, Cancer Biol, vol.10, pp.658-664, 2010. ,
, Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature, vol.499, pp.43-49, 2013.
, Cancer Genome Atlas Research Network
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma, N. Engl. J. Med, vol.374, pp.135-145, 2016. ,
The somatic genomic landscape of chromophobe renal cell carcinoma, Cancer Cell, vol.26, pp.319-330, 2014. ,
MiT family translocation renal cell carcinoma, Semin. Diagn. Pathol, vol.32, pp.103-113, 2015. ,
Genomic heterogeneity of translocation renal cell carcinoma, Clin. Cancer Res, vol.19, pp.4673-4684, 2013. ,
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma, Cell. Rep, vol.14, pp.2476-2489, 2016. ,
Collecting duct carcinoma versus renal medullary carcinoma: An appeal for nosologic and biological clarity, Am. J. Surg. Pathol, vol.38, pp.871-874, 2014. ,
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia, Am. J. Surg. Pathol, vol.37, pp.1469-1489, 2013. ,
Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling, Eur. Urol, vol.70, pp.516-521, 2016. ,
Renal Medullary Carcinoma: Establishing Standards in Practice, J. Oncol. Pract, vol.13, pp.414-421, 2017. ,
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes, Clin. Genitourin. Cancer, vol.15, pp.987-994, 2017. ,
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations, Eur. Urol, vol.70, pp.348-357, 2016. ,
Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol, vol.14, pp.1014-1022, 2013. ,
Oncology meets immunology: The cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013. ,
Armed response: How dying cells influence T-cell functions, Immunol. Rev, vol.241, pp.77-88, 2011. ,
Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response, Cancer Res, vol.72, pp.6325-6332, 2012. ,
Molecular pathways: Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1, Clin. Cancer Res, vol.18, pp.6580-6587, 2012. ,
Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol, vol.9, pp.162-174, 2009. ,
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat. Med, vol.2, pp.1096-1103, 1996. ,
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, vol.92, pp.4150-4166, 1998. ,
The impact of hypoxia on tumor-associated macrophages, J. Clin. Investig, vol.126, pp.3672-3679, 2016. ,
Myeloid suppressor cells in cancer and autoimmunity, J. Autoimmun, vol.85, pp.117-125, 2017. ,
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, J. Exp. Med, vol.212, pp.139-148, 2015. ,
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming, Nature, vol.544, pp.250-254, 2017. ,
It's T Time for Normal Blood Vessels, Dev. Cell, vol.41, pp.125-126, 2017. ,
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol, vol.13, pp.688-696, 1995. ,
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie, N. Engl. J. Med, vol.338, pp.1272-1278, 1998. ,
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015. ,
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study, J. Clin. Oncol, vol.35, pp.3851-3858, 2017. ,
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial, Lancet Oncol, vol.17, pp.883-895, 2016. ,
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N. Engl. J. Med, vol.373, pp.23-34, 2015. ,
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018. ,
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma, Cancer Biol, vol.18, pp.547-551, 2017. ,
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother. Cancer, vol.6, issue.9, 2018. ,
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study, J. Immunother. Cancer, vol.6, 2018. ,
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med, vol.24, pp.749-757, 2018. ,
Axitinib for the treatment of advanced renal cell carcinoma, Expert Opin. Pharm, vol.15, pp.283-297, 2014. ,
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial, Lancet Oncol, vol.19, pp.451-460, 2018. ,
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1103-1115, 2019. ,
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1116-1127, 2019. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009. ,
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma, Cancer Immunol. Res, vol.4, pp.12-17, 2016. ,
Guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-152, 2017. ,
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy, J. Clin. Oncol, vol.36, pp.850-858, 2018. ,
The devil is in the details, Ann. Oncol, vol.28, pp.1676-1678, 2017. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria, Clin. Cancer Res, vol.15, pp.7412-7420, 2009. ,
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial, Clin. Cancer Res, 2019. ,
Prognostic impact of PD-1 and its ligands in renal cell carcinoma, vol.34, p.99, 2017. ,
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project, J. Thorac. Oncol, vol.13, pp.1302-1311, 2018. ,
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens, Am. J. Clin. Pathol, vol.151, pp.217-225, 2019. ,
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy, Pathol. Res. Pract, vol.214, pp.1110-1114, 2018. ,
Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain, Acta Pharm. Sin, vol.26, pp.462-468, 2005. ,
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1, Mol. Diagn, vol.21, pp.85-93, 2017. ,
Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma ,
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status, Ann. Surg. Oncol, vol.23, pp.694-702, 2016. ,
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy, Target Oncol, vol.12, pp.487-494, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01578072
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression, Oncotarget, vol.8, pp.103428-103436, 2017. ,
PD-L1 expression in nonclear-cell renal cell carcinoma, Ann. Oncol, vol.25, pp.2178-2184, 2014. ,
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting, Clin. Cancer Res, vol.21, pp.1329-1339, 2015. ,
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer-Data from a Randomized Phase III Trial. Cancer Discov, 2019. ,
Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N. Engl. J. Med, vol.377, pp.2500-2501, 2017. ,
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups, Cancer Immunol. Res, vol.4, pp.820-822, 2016. ,
Signatures of mutational processes in human cancer, Nature, vol.500, pp.415-421, 2013. ,
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis, Lancet Oncol, vol.18, pp.1009-1021, 2017. ,